Antimicrobial resistance necessitates action to reduce and eliminate infectious disease, ensure animal and human health, and combat emerging diseases. Species such as Acinetobacter baumanniii, vancomycin resistant Enterococcus, methicillin resistance Staphylococcus aureus, and Pseudomonas aeruginosa, as well as other WHO priority pathogens, are becoming extremely difficult to treat. In 2017, the EU adopted the “one health” approach to combat antibiotic resistance in animal and human medicine and to prevent the transmission of zoonotic disease. As the current therapeutic agents become increasingly inadequate, there is a dire need to establish novel methods of treatment under this one health Framework. Bacteriophages (phages), viruses infecting bacterial species, demonstrate clear antimicrobial activity against an array of resistant species, with high levels of specificity and potency. Bacteriophages play key roles in bacterial evolution and are essential components of all ecosystems, including the human microbiome. Factors such are their specificity, potency, biocompatibility, and bactericidal activity make them desirable options as therapeutics. Issues remain, however, relating to their large-scale production, formulation, stability, and bacterial resistance, limiting their implementation globally. Phages used in therapy must be virulent, purified, and well characterized before administration. Clinical studies are warranted to assess the in vivo pharmacokinetics and pharmacodynamic characteristics of phages to fully establish their therapeutic potential.

中文翻译：

---

噬菌体和抗多种药物耐药性的一种健康方法：这是方法吗？

抗菌素耐药性必须采取措施减少和消除传染病，确保动物和人类健康，并抵抗新出现的疾病。物种，例如不动杆菌属baumanniii，耐万古霉素肠球菌，耐甲氧西林金黄色葡萄球菌，和铜绿假单胞菌以及世界卫生组织的其他优先病原体，变得极为难以治疗。2017年，欧盟采取了“一种健康”的方法来对抗动物和人类医学中的抗生素耐药性并防止人畜共患疾病的传播。由于当前的治疗剂变得越来越不足，迫切需要在这一健康框架下建立新颖的治疗方法。噬菌体（噬菌体）是感染细菌物种的病毒，对一系列耐药物种表现出明显的抗菌活性，具有很高的特异性和效力。噬菌体在细菌进化中起关键作用，并且是包括人类微生物组在内的所有生态系统的重要组成部分。这些因素包括其特异性，效力，生物相容性，和杀菌活性使其成为治疗的理想选择。然而，与它们的大规模生产，配制，稳定性和细菌抗性有关的问题仍然存在，限制了它们在全球的应用。在给药前，用于治疗的噬菌体必须具有毒性，纯度和良好的特性。有必要进行临床研究以评估噬菌体的体内药代动力学和药效动力学特征，以充分确立其治疗潜力。